GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes

Diabetes Research and Clinical Practice

Volumn 85, Issue 1, 2009, Pages 1-3

  Holst, Jens Juul ^a   Seino, Yutaka ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Beta cell function; GLP 1; Glycaemic control

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR STIMULATING AGENT; GLUCOSE; HEMOGLOBIN A1C; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL;

ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 67349236690     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.02.017     Document Type: Editorial

References (21)

1. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007) 1409-1439
2. Nauck M., Stöckmann F., Ebert R., and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
3. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267 (1992) 7402-7405
4. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43 (2000) 1664-1669
5. Marre M., Shaw J., Brandle M., Wan Bebakar W.M., Kamaruddin N.A., Strand J., et al. Liraglutide added to a sulphonylurea (SU) offers significantly better control and favourable weight change compared with rosiglitazone and SU combination in T2D. Diabetologia 51 Suppl. 1 (2008) S359 (Abstract 897)
6. Nauck M.A., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care (2008) (published online 10.2337/dc08-1355)
7. Garber A., Henry R., Ratner R., Garcia-Hernadez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (2008) 10.1015/S0140-6736(08)61246-5
8. Zinman B., Gerich J., Buse J., Lewin A., Schwartz S.L., Raskin P., et al. Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial. Diabetologia 51 Suppl. 1 (2008) S359 (Abstract 898)
9. Russell-Jones D., Vaag A., Schmitz O., Sethi B., Lalic N.M., Antic S., et al. Significantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin+ sulphonylurea in type 2 diabetes. Diabetologia 51 Suppl. 1 (2008) S68 (Abstract 148)
10. L. Blonde, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J. Brett, et al., Liraglutide: superior glycemic control vs. exenatide when added to metformin and/or SU in type 2 diabetes, Can J Diabetes 32 (Suppl.) (in press) (Abstract 107).
11. Seino Y., Rasmussen M.F., Zdravkovic M., and Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 81 (2008) 161-168
12. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
13. Buse J.B., Klonoff D.C., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther. 29 (2007) 139-153
14. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
15. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24 (2008) 275-286
16. Fineman M.S., Shen L.Z., Taylor K., Kim D.D., and Baron A.D. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab. Res. Rev. 20 (2004) 411-417
17. Irie S., Matsumura Y., Zdravkovic M., Jacobsen L.V., and Kageyama S. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int. J. Clin. Pharmacol. Ther. 46 (2008) 273-279
18. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
19. Rolin B., Larsen M.O., Gotfredsen C.F., Deacon C.F., Carr R.D., Wilken M., et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 283 (2002) E745-E752
20. Xu G., Stoffers D.A., Habener J.F., and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
21. Bregenholt S., Møldrup A., Blume N., Karlsen A.E., Nissen Friedrichsen B., Tornhave D., et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330 (2005) 577-584